Tenaya therapeutics publishes preclinical data in circulation highlighting the clinical potential of cellular reprogramming for cardiac regeneration

South san francisco, calif., oct. 02, 2023 (globe newswire) -- tenaya therapeutics, inc. (nasdaq: tnya), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publication of preclinical research in the october 3, 2023 issue of the american heart association's (aha) journal, circulation.
TNYA Ratings Summary
TNYA Quant Ranking